Fresolimumab
As of the edition of 20 October 2026, Fresolimumab is an antibody: stopped in 2013; acts on TGFB1, TGFB2 and TGFB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Antibody
- Registered trials
- 11, 1 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 5 | 0 | 1 |
| Phase 2 | 5 | 5 | 0 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2005 to now |